![]() ![]() ![]() The assay is reported in the form of a normalized ratio of PML/RARA (promyelocytic leukemia/retinoic acid receptor alpha) fusion transcript to the control gene ABL1 expressed as a percentage, which is an estimate of the level of PML/RARA RNA present in the specimen, expressed in relation to the level of RNA from an internal control gene ( ABL1). This quantitative assay allows PML/RARA levels to be monitored rather than simply detecting the presence or absence of disease. Recent studies have indicated that sensitive monitoring is important because the majority of patients who remain PCR positive, or become PCR positive again following treatment, will relapse and will likely benefit from early intervention for residual/recurrent disease. The PCR-based assay has greater sensitivity than standard methods such as morphology review, karyotyping, or f luorescence in situ hybridization. Messenger RNA produced from the fusion gene can be detected using a polymerase chain reaction (PCR)-based assay and indicates the presence of neoplastic cells. The fusion gene is designated PML/RARA and may be seen in a karyotype as t(15 17)(q22 q12). APL cells contain a fusion gene comprised of the downstream sequences of the retinoic acid receptor alpha gene ( RARA) fused to the promoter region and upstream sequences of one of several genes, the most common (>80%) being the promyelocytic leukemia gene ( PML). Acute promyelocytic leukemia (APL) accounts for 5% to 10% of acute myeloid leukemia and, generally, has a good prognosis with current treatment protocols. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |